Aluminium glycinate:Exports & Compliance White Paper 2026

I. Executive Summary

Aluminium glycinate (CAS 13682-92-3), pharmacopoeially dihydroxyaluminium aminoacetate, is a 1:1 chelate in which glycine binds an aluminium centre through carboxylate oxygen and amine nitrogen (C2H6AlNO4, Mr 135.06, theoretical aluminium about 19.9%). A white, odourless powder, insoluble in water and organic solvents but soluble in dilute acids and alkali hydroxide solutions, it serves two industries at once: an established antacid active substance and pharmaceutical excipient, and a mild astringent, buffer and absorbent for cosmetics, powders and oral care. The same compound may be released against a pharmacopoeial specification or a cosmetic heavy-metals specification, and the documentation behind those paths is not interchangeable.

Pharmaceutical demand is inelastic, tied to mature over-the-counter dyspepsia and reflux portfolios where decisions turn on monograph compliance, acid-neutralising capacity, tablet compressibility and suspension stability; growth is modest and concentrated in generic and store-brand formats. Cosmetic demand is more volatile: aluminium-free underarm marketing and scrutiny of aluminium exposure are cutting tonnage in antiperspirants while raising the documentation bar for the ingredients that remain.

This paper covers the process variables that set aluminium content, glycine ratio, pH and solubility; the grading logic separating cosmetic, pharmacopoeial and GMP-supported material; market structure and pricing; the European, United States and Chinese instruments governing placement; ESG exposure inherited from aluminium refining; and the packaging, dust control and logistics that keep a hygroscopic powder stable in transit. It is written for sourcing, quality and regulatory professionals and CDMO partners, and offers no dosage, formulation or self-administration guidance.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

Performance in both end uses follows from the amphoteric aluminium centre and the buffering zwitterion. In gastric acid the solid dissolves progressively, neutralising hydrochloric acid while glycine moderates the pH trajectory. In cosmetics the same surface chemistry gives mild astringency and binding of volatile fatty acids. Buyers should treat aluminium content, nitrogen, suspension pH and loss on drying as coupled attributes rather than independent specification lines.

• Chelation structure and monograph limits: The USP monograph requires not less than 94.0% and not more than 102.0% of C2H6AlNO4 on the dried basis, nitrogen between 9.90% and 10.60%, pH of 6.5 to 7.5 for a 1 g in 25 mL suspension, and loss on drying not more than 14.5%, fixing stoichiometry and hydration state together.
• Particle engineering and dissolution behaviour: Practically insoluble in water, the material performs by surface area, so median particle size of 5 to 20 micrometres and controlled bulk density govern acid-neutralising capacity per gram, suspension sedimentation, tablet hardness and mouthfeel.

2.2 Synthesis and Manufacturing Technologies

Industrial manufacture is the complexation of glycine with an aluminium source in water or alcohol, followed by drying and classified milling. Route selection turns on three questions: which aluminium source keeps chloride, sulfate and sodium within specification; how molar ratio and end-point pH are held so the dried solid lands inside the assay and nitrogen windows; and how the cake is dried without loss of coordination water. Drying, milling and blending therefore form part of the process definition.

• Aluminium hydroxide complexation: Glycine is slurried with activated aluminium hydroxide in water under heat and held near neutral pH, then filtered, washed and dried. The route is inexpensive and chloride-free but sensitive to hydroxide ageing and carbonation, so it needs tight raw-material specifications, defined wash endpoints and in-process assay correction.
• Aluminium isopropoxide and salt-based routes: These give faster, more complete complexation with very low chloride and sulfate, suiting oral-care and parenteral-adjacent grades, at the cost of solvent recovery and ICH Q3C residual-solvent justification. Tray, vacuum or spray drying then sets hydration, particle size and dust behaviour.

2.3 Core Application Matrix

• Antacid active substance and excipient: Used in tablets, chewables and oral suspensions, often with magnesium hydroxide or simethicone, it requires pharmacopoeial release, GMP documentation and — where it functions as an excipient — IPEC EXCiPACT or an equivalent audited qualification.
• Cosmetic astringent, buffer and absorbent: In deodorants, body powders, dentifrices and masks it is specified on lead, arsenic, cadmium and mercury, microbial limits and particle size, with its aluminium contribution reconciled against the finished product's category limit.
• Industrial and speciality uses: Rubber and polymer compounding, paper and coatings, flame-retardant synergists, feed premixes and analytical standards, where price, flow, whiteness and lot-to-lot consistency of bulk density matter more than assay precision.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Pharmaceutical volumes follow established over-the-counter antacid brands and their generic equivalents, driven by seasonality rather than innovation cycles and capped by the shift of reflux therapy toward proton-pump inhibitors and H2 antagonists. Aluminium-magnesium combinations keep the ingredient in specifications even when it is not the headline active. Cosmetic demand is moving the other way: aluminium-reduction claims cut tonnage in antiperspirants while raising the bar for the aluminium ingredients that remain.

3.2 Capacity Distribution and Export Flows

Capacity is concentrated in China, which supplies commodity and pharmacopoeial grades to Asia, the Middle East and Latin America and increasingly to European distributors that re-release material under their own quality systems. India adds domestic production plus a formulation and re-export business converting powder into finished antacids. Europe and North America retain a smaller, higher-value tier operating under excipient or API GMP and holding technical packages or master files.

3.3 Market Bifurcation and Pricing Dynamics

The market is sharply bifurcated. Industrial material trades as a commodity priced off glycine, aluminium hydroxide and energy. Pharmacopoeial grade commands a multiple of that price, and the premium is paid almost entirely for documentation: validated methods, elemental-impurity data, stability studies, audit readiness and master-file support. A middle tier — cosmetic grade with tightened heavy metals and microbial limits but no GMP claim — is growing fastest.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

One substance, two regulatory tracks. Pharmaceutical placement is gated by pharmacopoeial monographs, GMP and the importing country's marketing authorisation or over-the-counter monograph system; cosmetic placement by ingredient inventories, category-specific aluminium limits and safety substantiation. Suppliers who ship identical material to both tracks without separating documentation, labelling and end-use declarations create a gap that usually surfaces during an audit rather than at customs.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH registration and CLP notification: EU placement requires registration for the relevant tonnage band, with non-EU producers appointing an Only Representative under Article 8 of Regulation (EC) No 1907/2006. The substance is widely notified as not classified under CLP, though some dossiers carry eye-irritation or dust statements, so classification must come from the current supplier SDS, not an aggregator.
• Cosmetics Regulation 1223/2009 and aluminium limits: Finished cosmetics require a responsible person, INCI-based labelling, a qualified safety assessment and CPNP notification. Antiperspirant aluminium salts are restricted Annex III entries, and reported recent amendments — an aluminium entry introduced by Commission Regulation (EU) 2026/909, with limits reported at about 7.73% aluminium for non-aerosol antiperspirants and deodorants, 3.24% for aerosols and 3.18% for toothpaste — must be read from the official EUR-Lex text, since scope and transition dates determine whether legacy products remain marketable.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA inventory status and OSHA communication: The substance must be active on the TSCA Inventory for the relevant commercial activity, verified with EPA rather than assumed from a commercial listing, with a Hazard Communication-compliant SDS and label. Although normally shipped unclassified, aluminium dust is managed against occupational exposure limits for aluminium and insoluble aluminium compounds and against nuisance-dust limits, using local exhaust ventilation, dust suppression at emptying and defined respiratory protection.
• FDA frameworks, MoCRA and elemental impurities: Antacid finished products fall within the over-the-counter monograph system at 21 CFR Part 331, and buyers must confirm the current status of dihydroxyaluminium aminoacetate with regulatory counsel. An antiperspirant claim turns a cosmetic into an OTC drug under 21 CFR Part 350, and this ingredient is not among the listed actives. Cosmetics without a drug claim carry MoCRA obligations including facility registration, product listing and safety substantiation. Elemental impurities are assessed under ICH Q3D, noting that aluminium has no permitted daily exposure and is controlled through monographs and regional requirements.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

The material inherits a large upstream footprint unrelated to the complexation step. Carbon and residue intensity sit in bauxite mining, alumina refining and electrolysis and land in the customer's Scope 3, which is why regulated-market buyers ask about aluminium provenance. The conversion stage is comparatively benign: aqueous or alcoholic chelation at moderate temperature with no stoichiometric organic waste.

5.1 Carbon Footprint and Circular Economy

Embodied carbon is dominated by the aluminium source; producers who document refinery origin, Scope 1 and 2 disclosure and stewardship participation materially reduce customer exposure. Conversion contributes through drying, milling and solvent distillation, and reductions come from heat recovery, closed-loop isopropanol recovery, mother-liquor recycle and wash-water reuse. Waste is spent filter cake, aluminium-bearing wash water and packaging; effluents must meet local discharge limits and packaging should align with the EU packaging waste framework.

5.2 Sustainable Sourcing and Traceability

Traceability now reaches the refinery and the glycine route, whose chloroacetic acid ammonolysis or hydantoin and enzymatic variants carry different chloride and solvent profiles. Expected practice includes ISO 14001 and ISO 9001 systems, lot genealogy from raw material lots to finished pallet, audits of upstream producers and retained samples. For GMP customers it also means validated cleaning and segregation, with verification for aluminium carryover on shared trains.

VI. Supply Chain Resilience and Export Logistics

Logistically forgiving but not failure-free, the material is a fine, dust-forming, mildly hygroscopic powder that cakes under humidity and compression and is sensitive to over-drying during reprocessing. Normally shipped unclassified, its real risks are moisture pickup, bag abrasion, pallet compression and, for GMP lots, broken seals. Dual sourcing is advisable because documented capacity is small.

6.1 Packaging Standards and Moisture/Contamination Control

• Barrier packaging and sealing: Standard supply is 25 kg multiwall kraft bags with a polyethylene liner or fibre drums with tamper-evident seals; larger buyers take antistatic, sift-proof FIBCs. Liners should be sealed under controlled humidity, desiccant added for tropical sea legs, and pallets stretch-wrapped and top-capped against compression caking.
• Dust control, segregation and storage: Warehouses should be cool, dry and ventilated, with local exhaust at emptying stations, grounded equipment and segregation from strong acids, alkalis and other metal salts. Store off the floor, rotate first-expiry-first-out with a 24 to 36 month retest period, and re-assay loss on drying before reprocessing.

6.2 Dangerous Goods Identification and Transit Protocols

Aluminium glycinate is generally not classified as a dangerous good under ADR, IMDG or IATA and is consigned as unrestricted cargo where the SDS supports that position, though classification should be confirmed lot by lot because databases disagree. Transit discipline is therefore about preserving quality: moisture-protective liners or desiccant on long sea legs, routing that avoids container rain, temperature logging to hot and humid destinations, and sealed tamper-evident packaging with lot-level documentation for GMP shipments.

VII. Enterprise Global Expansion Strategy Guide

Suppliers should choose which track to serve, because the investments differ and a half-committed position tends to fail both. The commodity track competes on cost, consistency and freight; the documented track on dossier quality, audit performance and change-control discipline.

1. Build the dossier before the campaign: Establish validated monograph release methods, a documented elemental-impurity assessment covering aluminium, lead, arsenic, cadmium and mercury, real-time and accelerated stability with defined retest periods, and an open-part technical package or drug master file, plus IPEC EXCiPACT, ISO 9001 and ISO 14001 certification so audits convert into qualified-supplier status.
2. Segment the two tracks operationally: Run cosmetic and pharmacopoeial campaigns on dedicated or demonstrably cleaned equipment with separate specifications, labels, SDS versions and retention samples, and require a written end-use declaration from every customer. Offer cosmetic customers an aluminium-reconciliation tool and pharmaceutical customers a performance dossier covering acid-neutralising capacity, particle size, flow and compaction.
3. De-risk upstream and route to market: Dual-qualify aluminium hydroxide or alumina and glycine suppliers with known synthesis routes and documented carbon credentials, hold safety stock of both, pair direct supply to large formulators with qualified European and North American distribution, appoint an EU Only Representative where required, and use air-freighted validation lots before sea-freighted commercial volumes.

VIII. Conclusion

Aluminium glycinate will not be reshaped by innovation. It is a mature, dual-use compound whose outcome is decided by documentation discipline. Pharmaceutical value accrues to producers holding assay, nitrogen, pH, loss on drying, acid-neutralising performance and particle engineering inside a validated system, and who understand that aluminium control runs through monographs rather than an ICH Q3D permitted daily exposure, which does not exist for aluminium. Cosmetic value accrues to producers whose impurity and aluminium-reconciliation data let customers defend formulations against category limits.

For buyers the guidance is equally specific: state the end use in the purchase specification, require lot-level elemental-impurity data rather than a generic certificate, verify transport classification from the current SDS, and audit drying, milling and cleaning rather than only the reactor. For regulated finished products, insist on change-control notification and a qualified alternate source. Nothing here is dosage, formulation or self-administration guidance, and regulatory positions must be confirmed against current official texts.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Aluminium glycinate Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Aluminium glycinate supply chain:

• China production and export base: Chinese producers anchor global tonnage, combining contracted glycine supply with aluminium hydroxide or alumina from domestic refineries. The ecosystem spans commodity plants serving rubber, paper and coatings, upgraded lines producing cosmetic-grade powder with tightened heavy metals, and a smaller group running ISO and GMP-aligned systems that supply pharmacopoeial material to export customers and multinational distributors.
• India formulation and re-export hub: India combines domestic complexation capacity with a large generic and over-the-counter formulation industry that converts powder into finished antacid tablets and suspensions. Participants are strongest in cost-competitive supply to Africa, South Asia, the Middle East and Latin America and in documented supply to semi-regulated tender markets, with traders handling consolidation, freight and documentation.
• Europe and North America documented tier: Western producers and toll converters occupy the high-documentation end, operating excipient or API GMP systems, holding master files or open-part dossiers, maintaining REACH registration or Only Representative arrangements and supplying formulators that require audited sources. Specialist distributors add warehousing, lot-level documentation, change-control communication and aluminium-reconciliation support.